Filters
1Amgen collaboration; BeiGene has China commercial rights. 2Ensem collaboration; BeiGene has global rights. 3DualityBio collaboration; BeiGene has global clinical, manufacturing, and commercialization rights. 4Leads Biolabs collaboration; BeiGene has global research, development, and manufacturing rights, and exclusive commercialization rights outside of China. 5Zymeworks/Jazz collaboration; BeiGene has exclusive development and commercialization rights in Asia (except Japan), Australia, and New Zealand. 6Amgen collaboration; BeiGene has development and commercialization rights in China. 7Amgen collaboration; BeiGene has development and commercialization rights in China. aIn combination with Zanubrutinib. bMay include: PD-1 mAb, LAG3 mAb, OX40 mAb, TIM3 mAb, HPK1 inhibitor. * Trial is listed on clinicaltrials.gov, but may not have subjects enrolled.